AR099931A1 - Combinaciones de agentes terapéuticos contra cáncer - Google Patents
Combinaciones de agentes terapéuticos contra cáncerInfo
- Publication number
- AR099931A1 AR099931A1 ARP150100982A ARP150100982A AR099931A1 AR 099931 A1 AR099931 A1 AR 099931A1 AR P150100982 A ARP150100982 A AR P150100982A AR P150100982 A ARP150100982 A AR P150100982A AR 099931 A1 AR099931 A1 AR 099931A1
- Authority
- AR
- Argentina
- Prior art keywords
- acceptable salts
- physiologically acceptable
- combinations
- therapeutic agents
- against cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461974765P | 2014-04-03 | 2014-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099931A1 true AR099931A1 (es) | 2016-08-31 |
Family
ID=52692591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100982A AR099931A1 (es) | 2014-04-03 | 2015-04-01 | Combinaciones de agentes terapéuticos contra cáncer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9980966B2 (https=) |
| EP (1) | EP3125935B1 (https=) |
| JP (1) | JP6629753B2 (https=) |
| KR (1) | KR102410696B1 (https=) |
| CN (1) | CN106456752B (https=) |
| AR (1) | AR099931A1 (https=) |
| AU (1) | AU2015240094B2 (https=) |
| CA (1) | CA2944573C (https=) |
| ES (1) | ES2768900T3 (https=) |
| IL (1) | IL248126A0 (https=) |
| MX (1) | MX370540B (https=) |
| NZ (1) | NZ725361A (https=) |
| RU (1) | RU2733401C2 (https=) |
| SG (1) | SG11201608189WA (https=) |
| WO (1) | WO2015149909A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022101459A1 (en) * | 2020-11-16 | 2022-05-19 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
| WO2025168601A1 (en) * | 2024-02-05 | 2025-08-14 | Evexta Bio | Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| WO2004092154A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| AU2004278413B2 (en) | 2003-09-30 | 2008-07-31 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP4800216B2 (ja) | 2003-10-24 | 2011-10-26 | エグゼリクシス， インコーポレイテッド | ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法 |
| DE602004014969D1 (de) | 2003-11-21 | 2008-08-21 | Novartis Ag | 1h-imidazochinolinderivate als proteinkinaseinhibitoren |
| CN1889958A (zh) | 2003-12-09 | 2007-01-03 | 美国政府健康及人类服务部 | 抑制免疫应答或治疗增生性疾病的方法 |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| CA2590961C (en) | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| EP1902032A1 (en) | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
| CN101300029A (zh) * | 2005-11-04 | 2008-11-05 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| NZ595087A (en) | 2009-02-11 | 2013-03-28 | Merck Patent Gmbh | Novel amino azaheterocyclic carboxamides |
| CN102906118B (zh) | 2010-05-20 | 2017-07-28 | 埃博灵克斯股份有限公司 | 与her3相关的生物材料 |
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| PT2643313T (pt) * | 2010-11-24 | 2016-10-11 | Merck Patent Gmbh | Quinazolina carboxamida azetidinas |
| SG11201505999VA (en) * | 2013-03-11 | 2015-08-28 | Merck Patent Gmbh | 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
-
2015
- 2015-03-09 CA CA2944573A patent/CA2944573C/en active Active
- 2015-03-09 SG SG11201608189WA patent/SG11201608189WA/en unknown
- 2015-03-09 MX MX2016012825A patent/MX370540B/es active IP Right Grant
- 2015-03-09 EP EP15710714.5A patent/EP3125935B1/en active Active
- 2015-03-09 JP JP2016560799A patent/JP6629753B2/ja active Active
- 2015-03-09 RU RU2016143153A patent/RU2733401C2/ru active
- 2015-03-09 US US15/128,045 patent/US9980966B2/en active Active
- 2015-03-09 CN CN201580018245.XA patent/CN106456752B/zh active Active
- 2015-03-09 AU AU2015240094A patent/AU2015240094B2/en active Active
- 2015-03-09 ES ES15710714T patent/ES2768900T3/es active Active
- 2015-03-09 WO PCT/EP2015/000525 patent/WO2015149909A1/en not_active Ceased
- 2015-03-09 KR KR1020167030676A patent/KR102410696B1/ko active Active
- 2015-03-09 NZ NZ725361A patent/NZ725361A/en unknown
- 2015-04-01 AR ARP150100982A patent/AR099931A1/es unknown
-
2016
- 2016-09-29 IL IL248126A patent/IL248126A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2944573C (en) | 2022-10-25 |
| JP2017509683A (ja) | 2017-04-06 |
| EP3125935A1 (en) | 2017-02-08 |
| MX2016012825A (es) | 2017-01-05 |
| CA2944573A1 (en) | 2015-10-08 |
| CN106456752B (zh) | 2020-11-20 |
| KR102410696B1 (ko) | 2022-06-17 |
| AU2015240094A1 (en) | 2016-11-17 |
| WO2015149909A1 (en) | 2015-10-08 |
| BR112016020135A8 (pt) | 2021-07-06 |
| AU2015240094B2 (en) | 2020-07-30 |
| RU2016143153A3 (https=) | 2018-10-17 |
| EP3125935B1 (en) | 2019-10-23 |
| RU2733401C2 (ru) | 2020-10-01 |
| BR112016020135A2 (pt) | 2017-08-15 |
| MX370540B (es) | 2019-12-17 |
| NZ725361A (en) | 2022-09-30 |
| JP6629753B2 (ja) | 2020-01-15 |
| SG11201608189WA (en) | 2016-10-28 |
| CN106456752A (zh) | 2017-02-22 |
| US9980966B2 (en) | 2018-05-29 |
| KR20160133005A (ko) | 2016-11-21 |
| ES2768900T3 (es) | 2020-06-24 |
| RU2016143153A (ru) | 2018-05-04 |
| IL248126A0 (en) | 2016-11-30 |
| US20170100402A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013788A (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres. | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
| MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| MX2021006734A (es) | Metodo para tratar el cancer. | |
| CY1122469T1 (el) | Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης | |
| MX2018015100A (es) | Composicion y metodo para reducir la neutropenia. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| ECSP19057403A (es) | Usos terapéuticos de un polvo de insectos | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| BR112017010440A2 (pt) | administração sublingual de riluzol | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| DOP2016000120A (es) | Nuevos inhibidores de dgat2 | |
| MX388722B (es) | Compuestos para tratar el cancer de ovario. | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| EA201892098A1 (ru) | Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |